- Keywords
- kardioprotektivní látky,
- MeSH
- Cyclosporine administration & dosage immunology MeSH
- Adrenal Cortex Hormones administration & dosage pharmacology MeSH
- Hypertension chemically induced MeSH
- Hypoglycemic Agents administration & dosage pharmacology classification MeSH
- Immunosuppressive Agents administration & dosage immunology classification adverse effects MeSH
- Dipeptidyl-Peptidase IV Inhibitors administration & dosage pharmacology MeSH
- Phosphodiesterase 5 Inhibitors pharmacology classification metabolism adverse effects therapeutic use MeSH
- Insulin, Regular, Human therapeutic use MeSH
- Insulin Resistance MeSH
- Myocardial Ischemia chemically induced MeSH
- Ivabradine administration & dosage pharmacology MeSH
- Cardiotoxicity physiopathology prevention & control MeSH
- Cardiovascular Agents * administration & dosage pharmacology classification adverse effects MeSH
- Cardiovascular Diseases * drug therapy MeSH
- Contraindications, Drug MeSH
- Drug Interactions MeSH
- Humans MeSH
- Metformin administration & dosage pharmacology MeSH
- Muromonab-CD3 administration & dosage adverse effects MeSH
- Neoplasms complications MeSH
- Drug-Related Side Effects and Adverse Reactions MeSH
- Pentoxifylline administration & dosage MeSH
- Ranolazine administration & dosage pharmacology MeSH
- Glucagon-Like Peptide-1 Receptor agonists therapeutic use MeSH
- Arrhythmias, Cardiac chemically induced MeSH
- Heart Failure chemically induced MeSH
- Sulfonylurea Compounds administration & dosage pharmacology MeSH
- Tacrolimus administration & dosage adverse effects MeSH
- Heart Transplantation MeSH
- Trimetazidine administration & dosage pharmacology MeSH
- Thromboembolism chemically induced MeSH
- Check Tag
- Humans MeSH
- Publication type
- Review MeSH
Hlavní doménou využití monoklonálních protilátek v léčbě je onkologie a revmatologie. Využití tohoto typu biologické léčby v kardiologii bylo omezeno prakticky na protilátky vázající digoxin při digitalisové intoxikaci a na inhibici agregace trombocytů blokádou vazebných receptorů IIb/IIIa abciximabem. V roce 2015 však přicházejí dvě nové skupiny léčiv – inhibitory proproteinové konvertázy subtilisin/kexin 9, hypolipidemika alirocumab či evolocumab a antidotum proti dabigatranu (přímému inhibitoru trombinu) – idarucizumab. Také v dalších oblastech kardiologie je možno očekávat příchod nových zajímavých léčiv na bázi monoklonálních protilátek.
Monoclonal antibodies are mostly used in oncology and rheumatology. The use of this type of biological therapy in cardiology has been limited virtually to antibodies binding digoxin in digitalis intoxication and to inhibition of platelet aggregation by blocking the IIb/IIIa receptors with abciximab. In 2015, however, two novel classes of drugs have emerged: inhibitors of proprotein convertase subtilisin/kexin type 9, PCSK9, i.e. hypolipidemics alirocumab or evolocumab, and an antidote of dabigatran (direct thrombin inhibitor), i.e. idarucizumab. The emergence of novel interesting drugs based on monoclonal antibodies can be expected in other cardiology domains, too.
- Keywords
- alirocumab, evolocumab, idarucizumab,
- MeSH
- Abciximab MeSH
- Dabigatran antagonists & inhibitors MeSH
- Digoxin antagonists & inhibitors MeSH
- Dyslipidemias drug therapy therapy MeSH
- Hypolipidemic Agents pharmacology therapeutic use MeSH
- Platelet Aggregation Inhibitors therapeutic use MeSH
- Cardiovascular Diseases * drug therapy therapy MeSH
- Cholesterol, LDL drug effects MeSH
- Humans MeSH
- Antibodies, Monoclonal * pharmacology immunology therapeutic use MeSH
- Muromonab-CD3 MeSH
- Proprotein Convertases antagonists & inhibitors MeSH
- Serine Endopeptidases drug effects MeSH
- Thrombosis drug therapy prevention & control MeSH
- Check Tag
- Humans MeSH
Diabetes mellitus 1. typu představuje chronické onemocnění, které po své manifestaci významně a trvale mění život pacienta. V naprosté většině případů je spojené s doživotní aplikací inzulínu. Přesná substituční léčba inzulínem je nezbytná pro udržení glykémie v cílovém rozmezí s ohledem na riziko pozdních komplikací diabetu a minimalizaci rizika hypoglykémie. V současné době se klinicky testují strategie vedoucí k prevenci rozvoje diabetu 1. typu u rizikových osob nebo ke zpomalení progrese již rozvinuté autoimunitní poruchy vedoucí k destrukci B-buněk. Tyto preventivní strategie jsou založeny na biologické léčbě monoklonálními protilátkami. Zároveň je jasné, že tyto postupy ještě dlouhou dobu nebudou dostupné v běžné klinické praxi. Stále proto probíhá i vývoj zařízení pro dávkování inzulínu, které má pacientům umožnit účinnější, bezpečnější a kvalitnější léčbu inzulínem. Článek pojednává o současném stavu preventivních strategií diabetu 1. typu založených na biologické léčbě a novinkách ve vývoji a používání inzulínových pump.
Type 1 diabetes mellitus is a chronic disease that significantly and permanently changes the life of the patient once it is diagnosed. It almost always necessitates with lifetime insulin treatment. Precise dosage of insulin is necessary for maintaining blood sugar levels in the target range, in order to prevent late-onset diabetes complications and to minimize the risk of hypoglycaemia. Preventive strategies based on biological treatment with monoclonal antibodies are currently being tested for prevention of type 1 diabetes in high-risk subjects, or for slowing down the progression of autoimmune destruction of B-cells in subjects that are already affected. At the same time, it is clear that these strategies will not be available in clinical practice any time soon. Which is why development of insulin pumping devices continues and aims to ensure a more efficient, safe, and comfortable insulin treatment. This article reviews the emerging preventive strategies in Type 1 diabetes based on biological treatment and recent developments in insulin pumping devices.
- Keywords
- prevence diabetu, patch pumpy, kontinuální monitorace glykémie, Jewel Pump, Solo MicroPump, OmniPod, DANA Diabecare R, Accu-Chek Combo, Animas 2020, MiniMed Paradigm Veo, daclizumab, otelixizumab, teplizumab, V-Go,
- MeSH
- Abatacept MeSH
- Self Administration instrumentation MeSH
- Insulin-Secreting Cells drug effects MeSH
- Diabetes Mellitus, Type 1 drug therapy MeSH
- Etanercept MeSH
- Infusion Pumps, Implantable utilization MeSH
- Insulin Infusion Systems utilization MeSH
- Clinical Trials as Topic MeSH
- Humans MeSH
- Antibodies, Monoclonal therapeutic use MeSH
- Muromonab-CD3 therapeutic use MeSH
- Antibodies, Monoclonal, Murine-Derived therapeutic use MeSH
- Receptors, Tumor Necrosis Factor antagonists & inhibitors MeSH
- Rituximab MeSH
- Tumor Necrosis Factor-alpha antagonists & inhibitors MeSH
- Check Tag
- Humans MeSH
- MeSH
- Immunoglobulin G therapeutic use MeSH
- Immunosuppressive Agents therapeutic use MeSH
- Humans MeSH
- Antibodies, Monoclonal therapeutic use MeSH
- Muromonab-CD3 therapeutic use MeSH
- Graft Rejection prevention & control MeSH
- Kidney Transplantation immunology MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Comparative Study MeSH
- MeSH
- Drug Resistance, Microbial immunology drug effects MeSH
- Antilymphocyte Serum * administration & dosage adverse effects therapeutic use MeSH
- Adrenal Cortex Hormones therapeutic use MeSH
- Immune System Phenomena genetics immunology drug effects MeSH
- Immune System * immunology drug effects MeSH
- Immunosuppression Therapy methods trends utilization MeSH
- Humans MeSH
- Muromonab-CD3 administration & dosage adverse effects therapeutic use MeSH
- Drug-Related Side Effects and Adverse Reactions MeSH
- Graft Rejection drug therapy MeSH
- Statistics as Topic MeSH
- Kidney Transplantation methods utilization MeSH
- Transplantation Immunology * immunology drug effects MeSH
- Outcome and Process Assessment, Health Care MeSH
- Check Tag
- Humans MeSH
